Forodesine clinical trials
Includes 10 studies of Forodesine hydrochloride.
- studies test it
- 14
- open now
- 0
- in phase 3
- 0
- first study started
- 2001
How each study uses forodesine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
14 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
BioCryst Pharmaceuticals (10) · Mundipharma K.K. (2) · Mundipharma Research Limited (2)
Studies
Open first, then newest update. How each study uses forodesine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma PatientsCompletedPhase 1/2Mundipharma K.K.NCT01776411Written as forodesine hydrochloride
- Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell MalignanciesCompletedPhase 1Mundipharma K.K.NCT00823355Written as forodesine hydrochloride
- Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell LymphomaCompletedPhase 1BioCryst PharmaceuticalsNCT00098332Written as forodesine hydrochloride
- BCX-1777 in Treating Patients With Refractory CancerCompletedPhase 1BioCryst PharmaceuticalsNCT00073944Written as forodesine hydrochloride
- BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell LymphomaCompletedPhase 1/2BioCryst PharmaceuticalsNCT00061880Written as forodesine hydrochloride
- Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.TerminatedPhase 1/2Mundipharma Research LimitedNCT00742495Written as Forodesine
- Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2BioCryst PharmaceuticalsNCT00289549Written as forodesine hydrochloride (BCX-1777)
- Forodesine in the Treatment of Cutaneous T-Cell LymphomaCompletedPhase 2BioCryst PharmaceuticalsNCT00501735Written as Forodesine 200 mg
- Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2BioCryst PharmaceuticalsNCT00640523Written as forodesine HCl
- Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment RegimensTerminatedPhase 2BioCryst PharmaceuticalsNCT00419081Written as Forodesine Hydrochloride Capsules (100 mg)
- Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic LeukemiaCompletedPhase 1/2BioCryst PharmaceuticalsNCT00289562Written as forodesine hydrochloride (BCX-1777)
- Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell LeukemiaCompletedPhase 2BioCryst PharmaceuticalsNCT00095381Written as forodesine hydrochloride (BCX-1777)
- Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic LeukemiaTerminatedPhase 1Mundipharma Research LimitedNCT00646165Written as Forodesine
- Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or LymphomasCompletedPhase 1/2BioCryst PharmaceuticalsNCT00035022Written as BCX-1777
Codes
What other systems call forodesine · ClinicalTrials.gg INT004086
- MeSH (NLM) C113101forodesineOne source NLM
- UNII (FDA) 426X066ELKFORODESINEConfirmed FDA, NLM, Wikidata
- Wikidata Q410040forodesineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65755ForodesineOne source FDA
- DrugBank DB06185One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C113101 | forodesine | One source NLM |
| UNII (FDA) | 426X066ELK | FORODESINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q410040 | forodesine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65755 | Forodesine | One source FDA |
| DrugBank | DB06185 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.